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ABSTRACT OF THESIS 
 
REVERSIBLE DOWNREGULATION OF HYPOTHALAMIC-PITUITARY-
GONADAL AXIS IN THE STALLION WITH A THIRD-GENERATION GNRH 
ANTAGONIST 
 
The objectives of this thesis were: (1) to evaluate the downregulation of the stallion 
hypothalamic-pituitary-gonadal (HPG) axis by a GnRH antagonist (acyline) based upon 
endocrine, seminal, testicular and behavioral effects, and (2) to assess recovery after 
treatment. Stallions were treated for 50 days (n=4; 330µg/kg acyline q 5d) and controls 
(n=4) received vehicle alone. Stallions were assessed pre-treatment and for 72 days after 
last treatment. Treatment induced declines (p<0.05) in FSH, LH, testosterone (to castrate 
levels) and estrone sulfate. Gonadotropins and testosterone returned to control values 
within nine days and estrone sulfate by 14 days after treatment discontinuation. Acyline-
treated stallions failed to respond with FSH, LH and testosterone increase after exogenous 
GnRH stimulation (25µg gonadorelin, IV) compared to pre-treatment and control 
stimulation. Total sperm numbers and motility were reduced in acyline-treated stallions, as 
well as total seminal plasma protein and testicular volume (p<0.05). Time to ejaculation 
was increased in acyline group (p<0.5). Testicular, sexual behavior and most seminal 
parameters regained normal levels within 72 days after treatment ceased. Sperm output of 
acyline-treated stallions was regained within seven months after ending treatment. Acyline 
reversibly suppressed the stallion HPG axis, thus has potential for treating the androgen-
dependent Equine-Arteritis-Virus carrier state and as behavior modulator. 
KEYWORDS: Hypothalamic-pituitary-gonadal axis, GnRH antagonist, Stallion, Equine 
Arteritis Virus (EAV), Sexual Behavior. 
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Chapter One: Introduction 
Elimination of EAV (equine arteritis virus) carrier state and alteration of 
sexual/aggressive behavior are often cited as reasons to suppress gonadal activity in 
stallions Various outbreaks of equine viral arteritis (EVA) in the past decades have 
highlighted the important role of persistently infected stallions in disseminating the disease 
through infective semen (Timoney et al., 1986; Timoney et al., 1987; Timoney et al., 2006; 
Barrandeguy, 2010; Miszczak et al., 2012). As many as 30 to 60% of stallions develop a 
persistent carrier state after recovery from the acute phase of the infection (Neu et al., 1987; 
Timoney and McCollum, 1993). Establishment and maintenance of the viral shedding state 
has been shown to be androgen dependent (Little et al., 1991; Holyoak et al., 1993; 
McCollum et al., 1994), and removal of endogenous testosterone results in termination of 
persistent carrier state (Little et al., 1991). Castration has historically been the method of 
choice to manage stallions that present excessive display of sexual or aggressive behavior; 
even before such behavior was linked to estrogens and androgens (Thompson Jr. et al., 
1980; McDonnell, 1986; McDonnell et al., 1989). Orchiectomy seems to resolve most of 
the cases where sexual behavior may compromise training or performance of stallions 
(Line et al., 1985). However, the obvious irreversibility of surgical castration precludes the 
use of stallions for breeding after retirement from a successful athlete career. 
As an alternative to castration, different approaches for down-regulation of the 
hypothalamic-pituitary-gonadal (HPG) axis in the stallion have involved the use of the 
progestogen, altrenogest (Brady et al., 1997; Squires et al., 1997; Johnson et al., 1998; 
Goolsby et al., 2004) or immunization against GnRH (Dowsett et al., 1996; Malmgren et 
al., 2001; Turkstra et al., 2005; Janett et al., 2009). There is some uncertainty about the 
reversibility of reproductive function after discontinuation of these methods of treatment. 
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More recently, attempts to suppress the HPG axis of stallions with GnRH antagonists 
yielded a decline in FSH, LH and estradiol and seemed to decrease libido after a single 
injection of Antarelix (Hinojosa et al., 2001). Furthermore, Antarelix and a second GnRH 
antagonist, Cetrorelix,  given daily for 35-38 days, achieved a reversible decrease in 
testosterone, which was suggested to have had a causal relationship with EAV clearance 
in shedder stallions (Fortier et al., 2002). 
A potent, third-generation GnRH antagonist, acyline, was shown to decrease FSH 
and LH for at least 15 days, and to keep testosterone at castrate levels for 2 weeks after a 
single injection in men (Herbst et al., 2004). In male dogs, one dose of acyline caused FSH, 
LH and testosterone to decrease for at least nine days (Garcia Romero et al., 2009). Acyline 
treatment in dogs reversibly affected libido and erectile function (Valiente et al., 2007) and 
suppressed response of the HPG axis to exogenous GnRH stimulation (Garcia Romero et 
al., 2012b). This GnRH antagonist has been used mares to suppress FSH and retard 
follicular growth (Checura et al., 2009; Checura et al., 2010); however, there are no reports 
of its use in stallions. 
  To address the hypothesis that acyline treatment in stallions would reversibly down-
regulate the HPG axis, this study aimed to (1) determine the effects of acyline treatment on 
endocrine, seminal, and behavioral parameters and testicular volume of stallions; (2) 
determine responsiveness of acyline-treated stallions to exogenous GnRH stimulation; and 
(3) to examine the degree of recovery of these parameters after withdrawal of acyline 
treatment. 
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Chapter Two:  Literature Review 
2. Manipulation the Hypothalamic-pituitary-gonadal (HPG) axis 
2.1. Justifications for interference of reproductive endocrine function in stallions 
 There are a number of different reasons why it would be of interest to down-regulate 
the hypothalamic-pituitary-gonadal (HPG) axis in the stallion, including contraceptive 
measures. However, for this review we will focus on the control of equine arteritis virus 
and behavior modulation as reasons for suppression of the HPG of stallions.   
2.1.1 Equine Viral Arteritis 
A. History, epidemiology and economic impact 
The first equine arteritis virus (EAV) isolation (Doll et al., 1957b) was associated 
with an outbreak of respiratory disease and abortion in a Standardbred breeding farm in 
Ohio (Doll et al., 1957a). However, not many investigators considered equine viral arteritis 
(EVA) a disease of veterinary or economic significance until another outbreak occurred in 
1984. It was the first EAV outbreak recorded in the Thoroughbred population in the U.S.A 
and generated widespread interest and major concern to the equine industry (Timoney and 
McCollum, 1993). 
The importance of the disease was emphasized by a number of significant outbreaks 
of EVA that occurred in the last decade in North and South America as well as Europe. A 
2006  outbreak of EVA in the USA affected horses from different breeds – though initially 
American Quarter Horses – and spread across nine states (Timoney et al., 2006). The 
outbreak that occurred in Normandy, France, that affected only draft and saddle horses 
(Pronost et al., 2010; Miszczak et al., 2012); and the large 2010 outbreak in Argentina 
which affected mainly sport-horses, involved abortion rates up to 50% and resulted in 38 
 
4 
stallions becoming seropositive for EAV (Barrandeguy, 2010). All of these outbreaks could 
be traced back to EAV carrier stallions. 
Equine Arteritis Virus infection occurs in horses on every continent. 
Seroprevalence rates vary considerably, not only among countries, but among horse 
populations and breeds. In the USA, the infection is believed to be endemic in 
Standardbreds, with an average prevalence of 80%, whereas in Thoroughbreds, the 
seroprevalence is 2-3% (McCollum and Bryans, 1973; Timoney and McCollum, 1993). A 
serologic survey of horses imported to California from several countries demonstrated that 
the prevalence of EAV infection was also high in European Warmbloods – around 18% 
(Hullinger et al., 2001). 
Among the consequences associated with EAV infection, the most significant are 
the risk of abortions and the establishment of the carrier state in stallions. There are direct 
financial losses attributable to outbreaks of EAV-related abortion; rates can reach between 
50 and 60% of pregnant mares at risk. In addition, carrier stallions and ,(Timoney and 
McCollum, 1993) infective semen (Barrandeguy, 2010; Timoney, 2011) cannot be 
exported unless to the USA. Other financial consequences include veterinary and 
laboratory expenses; disruption of races, shows and other competitions; and 
inconveniences that result from movement restrictions (Barrandeguy, 2010). 
B. Virus transmission 
The development of clinical signs following natural or experimental infection of 
EVA can vary considerably in severity among individual horses and outbreaks, though the 
majority of cases are asymptomatic. Regardless of the severity of clinical signs, all 
naturally infected adult horses recover spontaneously from infection (Timoney and 
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McCollum, 1993; Timoney, 2011). Abortion rates between 10 and 60% have been reported 
in the case of natural outbreaks of the disease and they are not necessarily preceded by 
clinical signs of EVA (Timoney and McCollum, 1993). 
Transmission of EAV occurs mainly by the respiratory route from an acutely 
infected animal (Doll, Bryans, and Knappenberger, 1957; McCollum et al., 1971) or by the 
venereal route through the acutely or chronically infected stallion (Timoney, McCollum, 
Roberts, et al., 1986; Timoney et al., 1987). Transmission via the respiratory route requires 
direct contact between susceptible horses and acutely infected animals or their infective 
body secretions (Timoney and McCollum, 1993; Timoney, 2011). 
During the acute phase of the infection, stallions may experience diminished libido, 
in addition to impairment of sperm production, decreased sperm concentration and 
motility, and an increased percentage of morphologically abnormal sperm that may persist 
for up to 6-7 weeks or longer. Such a period of temporary subfertility have been shown to 
be due to increased testicular temperature associated with scrotal and preputial edema 
rather than a direct effect of the virus on the testes (Neu et al., 1992; Campos et al., 2014). 
Stallions acutely or persistently infected with EAV play a major role in the venereal 
transmission of EAV to mares during natural breeding and artificial insemination with 
fresh, cooled or frozen semen (Timoney et al., 1986; Timoney et al., 1987; Balasuriya et 
al., 1998). Approximately 85 to 100% of mares bred to long-term carrier stallions 
seroconvert to EAV within 28 days after breeding (Timoney and McCollum, 1993). Recent 
work has shown that embryo transfer from a donor mare inseminated with EAV infective 
semen to naive recipient mares could also represent a risk of EAV transmission, under 
experimental conditions (Broaddus et al., 2011).  
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C. EAV carrier stallion and persistent infection mechanisms 
After resolution of acute phase of infection with EAV, intact males may become 
chronically infected with EAV and constantly shed the virus in the ejaculate, despite high 
antibody titers to the virus in the circulation. It has been shown that the carrier state may 
last for several weeks, months or years (Timoney et al., 1986; Timoney et al., 1987; 
Timoney and McCollum, 1993). Studies of horse populations that experienced outbreaks 
of EVA indicated that stallions shedding EAV in their semen serve as a reservoir for the 
virus within equine populations (Timoney et al., 1986; Timoney et al., 1987). Timoney and 
colleagues verified that 47% of the stallions naturally infected with EAV during the 1984 
disease event became persistent carriers of the virus (Timoney et al., 1987). Population 
surveillance in the years following also indicated that the carrier rate was associated with 
breed, seemingly higher in Standardbreds than Thoroughbreds (Timoney and McCollum, 
1993, 2000) and overall the frequency of the carrier state after infection with EAV was 
between 30 and 60%. 
It has been demonstrated that the virus persists in the carrier stallion harbored in 
the accessory sex glands, and the ampulla of the vas deferens has the highest viral titers 
(Neu et al., 1987). The mechanism of EAV persistence, even though still not clear, was 
first shown by Little and collaborators to be testosterone dependent. In their study, long-
term EAV carrier stallions ceased to shed the virus in the ejaculate between 4 and 24 days 
after surgical castration, while castrated carriers supplemented with exogenous testosterone 
maintained viral output in the semen (Little et al., 1991). Additional data underscores the 
direct or indirect role of testosterone in the carrier state: persistent infection was not 
established in colts exposed to the virus before the onset of puberty (Holyoak et al., 1993), 
or in castrated males experimentally infected with the KY-84 strain of the virus (McCollum 
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et al., 1994). The event which induces spontaneous clearance of the shedding state in the 
persistently infected stallion is still unclear, but there is no indication that a stallion could 
revert back to shedding or become an intermittent shedder once it has stopped shedding the 
virus in its semen (Timoney and McCollum, 2000).  
One possible mechanism for long-term persistence of EAV infection in the 
reproductive tract of mature stallions could be a presumed suppressive activity of 
testosterone. Based on in vitro studies, testosterone is thought to reduce B-cell 
lymphopoiesis, diminish inflammatory cytokine production and inhibit the phagocytic 
capacity of macrophages (Muehlenbein and Bribiescas, 2005). It could also be that, as 
accessory sex glands depend on testosterone for their normal function (Thompson Jr. et al., 
1979), the hormone provides the trophic conditions for the virus population to thrive. It is 
also assumed that there is a continuous re-infection of susceptible tissues by the virus in 
the reproductive tract (Balasuriya et al., 1999).  
Recently Go and collaborators demonstrated that a common haplotype of CD3+ T 
cells is associated with resistance/susceptibility in-vitro to EAV (Go et al., 2011) and that 
such in-vitro susceptibility marker corresponded to the pattern of immune response in-vivo 
in infected horses. Populations of horses could also be divided into susceptible and resistant 
(Go et al., 2012b). Finally, the same author showed that in-vitro susceptibility of CD3+ T 
lymphocytes indicates a predisposition of naturally infected stallions to become 
persistently infected with EAV (Go et al., 2012a). 
A method to cope with EAV carrier state in order to utilize sperm of stallions still 
shedding the virus was studied by Morrell and coworkers. Virus particles were 
mechanically separated from sperm cells in extended semen through the use of 
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centrifugation - once or twice - over a single colloid (Androcoll-E) layer. After 
centrifugation, the infective virus numbers were reduced drastically, with no adverse effect 
on sperm motility. Nonetheless, there was still viral load present in the supernatant, which 
precludes the potential use of the procedure to process infected semen (Morrell et al., 
2013). 
2.1.2. Aggressive/sexual behavior modification 
A. Source of aggressiveness: From natural to artificially induced  
Environmental and dominance status as well as sex and age affect the type of 
aggressive behavior displayed by male horses.  Stallions can be threatening to subordinate 
horses in conflict situations during sexual interactions.  Interactions between stallions often 
involve ritualized displays and are of normal occurrence between disputing mature, free-
ranging stallions. This is thought to be a way to keep spacing and maintain social structure. 
It seems that interactions between two harem stallions tend to be less intense than between 
a harem and a bachelor stallion (Waring, 1983). 
Violent, non-ritualized aggression occasionally occurs between stallions. That 
happens with sudden charge of stallions toward one another, followed by biting, foreleg 
striking and hind leg kicking. Bloody wounds and broken bones can occur. Soon one of 
the individuals withdraws or is chased away. As expected, most aggressive interactions 
observed are from disputes over the harem male position in a herd (Waring, 1983; Beaver, 
1986; Keiper, 1986). 
Problems associated with dominance can occur in a number of situations in which 
horses interact with other horses or humans. When horses are exposed to new social groups, 
dominance hierarchies form as they would among band members in the wild. New horses 
introduced to a group must find their place within the social order, and during that short 
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time, threats and fights will occur between individuals of a herd (Keiper, 1986). With the 
limited opportunities for interactions environmental setting, aggressive acts may happen, 
and often unexpectedly (Keiper, 1986) 
In the specific case of colts and stallions, the natural occurrence of harem status 
influences reproductive endocrinology and function, including an increase in androgen 
levels and sexual/aggressive behavior. On the other hand, bachelor status imparts 
suppression the reproductive axis. Given the constant re-accommodation of sociosexual 
dynamics, as the dominance establishment mentioned above, it is no surprise that male 
horses, especially young ones, will often switch from one status (bachelor or harem) to the 
other (McDonnell, 1986; McDonnell and Murray, 1995). However, the transition 
encompasses displaying the behavior for a certain status, which can be in the form of rather 
unexpected behavior (McDonnel, 1986). 
 In-hand breeding procedures are also a source of contrast between the feral and 
domesticated environment. Also in this scenario, human interference can exacerbate the 
contrast experienced by the horse, characterized mainly by limitations of display of normal 
ethology that the horses would not find in the wild, or in a domestic context with little 
human intervention (McDonnell, 1986, 2000). Considering the marked difference in the 
opportunities for interaction before copulation compared to a free-range situation, it is quite 
remarkable that most domestic stallions can have what is considered normal domestic 
breeding career with such minimal precopulatory contact with mares. Some breeding farm 
managers recognize and accommodate these apparent needs, but some expect all stallions 
to do well with limited contact which may lead to various responses (McDonnell, 2000). 
Restraints applied to the mare often appear to provoke a change in response in mares that, 
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instead of being otherwise receptive, may show fear and resistance. While safety is an 
important concern, over restraint of the mare, modifying the interaction during copulation, 
can frustrate some stallions (McDonnell, 2000). As a result, abnormalities in the sexual 
behavior of stallions range from excessive biting and aggressiveness to the various forms 
of impotence and even fear of mares (Waring, 1983). Excessive aggression is an aberrant 
behavioral problem of some stallions. Frustration of high libido stallions caused by 
incomplete sexual interactions and repeated non-ejaculatory copulations appears involved 
in most cases (Waring, 1983).  It has been reported (McDonnell, 1995) that continuous 
teasing exposure to mares consistently increased testosterone concentrations and higher 
levels of sexual/aggressive behavior. 
B. Concern with aggressive stallion behavior in the industry 
Humans may encounter stallion aggression in two main ways: people may be 
injured when aggressive encounters occur between horses or when a horse considers itself 
dominant to the person (Beaver, 1986). In more extreme situations, although biting, 
striking and kicking are normal elements of precopulatory sequence, savage aggressiveness 
is one of the most serious behavioral problems. Many stallions are consistently aggressive, 
but some breeding stallions are uncontrollably or unpredictably aggressive toward mares 
or handlers (McDonnell, 1986). This sexual and aggressive behavior of stallions often 
inhibits the performance potential of these individuals and may also be dangerous to other 
horses, handlers, riders or others (Johnson et al., 1998; Stout and Colenbrander, 2004). 
Colts or stallions in training or competition that exhibit these undesired traits are considered 
by trainers to have adversely affected performance (Stout and Colenbrander, 2004) 
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C. Role of steroid hormones on sexual behavior  
Androgens are generally necessary for expression of stallion-like behavior. Even 
though administration of exogenous testosterone to intact normal stallions does not seem 
to improve sexual behavior it may lead to increased aggression (McDonnell, 1986). In 
addition, the very high concentration of estrogens in stallions, compared to males of other 
species (Raeside, 1969), mainly in the form of estrone (Seamans et al., 1991), led to 
experiments designed to determine the roles of testosterone and estradiol in the regulation 
of sexual behavior. Thompson and colleagues found that treatment of castrates with 
testosterone alone or combined with estradiol benzoate restored libido, and a similar effect 
was found with a high dose of estradiol benzoate. In the geldings supplemented with 
estradiol benzoate alone, libido appeared to be restored to a much greater extent than to the 
ability to ejaculate (Thompson Jr. et al., 1980). The authors suggested that peripheral or 
central aromatization of testosterone occurred. This observation agrees with the hypothesis 
that effects of testosterone in sexual behavior of males are mediated by aromatization to 
estradiol within the target neurons (Naftolin et al., 1971) and with the recent finding of 
aromatase expression in the brain of the stallion (Lemazurier et al., 2001). However, the 
possibility of a direct effect of testosterone on libido cannot be excluded. 
 McDonnell and co-workers found that GnRH induced precopulatory behavior (viz. 
attention, Flehmen response, erection duration) is testosterone dependent. The study 
illustrated that exogenous GnRH treatment influenced sexual behavior, though it required 
testosterone priming to occur (McDonnell et al., 1989).  
Puberty and an abrupt rise of circulating testosterone in colts around 80 weeks of 
age (about 1.5 years), ranging from 56 to 97 weeks, (Naden et al., 1990) in light-breed, 
cross-bred colts. In many breeds, like Thoroughbreds and Quarter horses, the occurrence 
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of those changes then coincides with the age when young horses are at some point of 
training, or even about to start racing or competing in shows.  
D. Castration as means of reducing aggressive behavior 
Male horses not intended for breeding are usually castrated during their second year 
of life or before, although some owners prefer delaying surgery until a later age, 
presumably to allow more substantial physical development and development of male 
secondary sexual characteristics (Trotter, 1989). Surgical castration is performed as an 
attempt to prevent development of objectionable sexual libido and aggression characteristic 
in stallions. A survey of horse owners evaluating castration as therapeutic measure to 
eliminate objectionable sexual/aggressive behavior toward people, found castration to be 
60 to 70% effective, which means that about 30% of castrated stallions continued to display 
some kind of aggressive behavior. When castration was done prior to puberty (before two 
years of age) to preclude development of such behavior, no difference was found compared 
to castration performed after three  years of age (Line et al., 1985). Despite the originality 
of the publication, it does not seem like “prepuberty” would not be the correct term, since 
most colts will have reached puberty months before 2 years of age (Naden et al., 1990). 
Besides the likelihood of sexual display in castrated males, castration has some 
associated risks, including: hemorrhage, septic funiculitis, and eventration, among others 
(Getman, 2009; Schumacher, 2013). Complications associated with equine orchiectomy 
have been cited as the most common cause of malpractice claims against veterinarians in 
North America (Wilson and Quist, 1992).  
According to The Jockey Club, approximately 25% of Thoroughbred racing horses 
are geldings, and many of these geldings were castrated because of behavioral problems 
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which interfered with training or racing.  Although many of these geldings would not have 
become successful sires had they not been castrated, numerous other geldings that have 
had successful race careers (e.g. Kentucky Derby winners), could have been genetically 
important sires. Also in the Quarter horse industry (Goolsby et al., 2004) owners and 
trainers are frequently faced with a dilemma of whether to castrate when dealing with a 
colt that is not performing or training up to expectations. To have the ability to temporarily 
suppress sexual and aggressive behaviors during training might permit the time necessary 
to efficiently evaluate the performance and breeding potential of the animal before a 
decision is made on whether to castrate the animal (Johnson et al., 1998). Some 
pharmacological approaches to castration in male horses are used to some extent as will be 
discussed below. 
2.2. Pharmacological approaches to down-regulate the Hypothalamic-pituitary-
gonadal (HPG) axis 
2.2.1. Steroids: progestogens and androgens 
The rationale for the use of progestagens for blocking the hypothalamic-pituitary 
axis in the mare is based on these compounds having a negative feedback on GnRH release, 
resulting in a decrease in circulating LH and FSH, as endogenous progesterone would 
(Garcia and Ginther, 1978; Ginther et al., 2006). While different compounds can be used 
for this purpose, the oral progestin altrenogest is the most widely used progestagen in mares 
(Roberts and Beaver, 1987). Even though the administration of altrenogest to stallions is 
off-label, it is also used in the equine industry (Heninger et al., 2001) to modify sexual and 
aggressive behavior. 
As discussed above, the aggressive behavior exhibited by some stallions during 
performance can harm their success in shows or at the race track. Potentially, progestins 
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could be used to decrease libido and aggressive behavior.  However, there is question on 
how effective they are in modifying behavior and concern about long-term detrimental 
effects that might result from such treatment in stallions.  
A study using the label dose of altrenogest for estrous suppression in mares (0.44 
mg/kg daily) for a  30 day treatment in stallions showed no differences in semen quality or 
behavior for stallions greater than five years of age (Miller et al., 1997). Another study 
(Johnson et al., 1998) performed in young stallions (2-4 years old), using a high dose of 
altrenogest (0.88 mg/kg) for 57 days found that the progestin treatment decreased testicular 
size and function and compromised libido (Flehmen response, penis exposure and erection) 
without affecting body development. Testosterone and estradiol were reduced in this study 
during treatment but recovered after cessation of treatment. However, their data did not 
show reversibility of the detrimental effects on daily sperm output (DSO), scrotal size nor 
libido within an 8-week recovery period after the end of treatment (Brady et al., 1997)  
One long-term study by Squires and colleagues investigated the effects of a 150 or 
240 day altrenogest (0.88mg/kg SID) treatment on semen characteristics, testicular size, 
circulating LH and testosterone and libido of 3 to 18 year old stallions. Treatment decreased 
all parameters, including libido as measured: time for erection, time for ejaculation and 
frequency of failure to ejaculate. During the 90 day recovery period, adverse effects on 
scrotal width, DSO and motility were no longer seen. However, resumption to normality 
after the prolonged treatment did not occur for LH and testosterone concentrations, sperm 
morphology or libido parameters. The authors suggested that since the experiment ended 
in a time of seasonal recrudescence (March) a longer recovery period could have allowed 
for restoration of all of the parameters (Squires et al., 1997). 
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 Heninger and co-workers (Heninger et al., 2001) undertook a 67-day treatment of 
2-year-old colts using the mare dosage of altrenogest (0.44mg/kg SID). No differences 
were seen in libido, subjective parameters like sniffing/licking, biting/chewing, 
vocalization, aggressive behavior towards mare or handler were analyzed and found to be 
unaffected by administration of the progestagen. Neither were there differences in 
testosterone due to treatment, but estrogen concentrations, thought to govern libido in the 
stallion (Thompson Jr. et al., 1980) were decreased by treatment and recovered after 
cessation. Heninger and co-authors stated that dose of altrenogest is associated with the 
efficacy of behavioral modification in the stallion. 
A survey (Goolsby et al., 2004) collected data on the use of altrenogest in in Quarter 
horse in training across the USA during 2002; out of 63 respondents, 29% reported the use 
of altrenogest in their stallions. Only 11% owners/trainers administered the progestagen to 
stallions being used for breeding, but 89% were treating stallions with the intention of using 
the stallion for breeding in the future. The main reason for altrenogest administration was 
to create a more focused animal in a performance setting, and also to reduce aggressiveness 
or create an easier stallion to handle. Even though altrenogest is widely used off-label, the 
available data does not warrant reversibility of the adverse effects of treatment. 
Trainers and owners may also administer androgens to stallions for improvement 
of performance, growth acceleration (particularly muscle mass) and an increase in libido. 
Such treatments cause a negative feedback on the hypothalamus (Muyan et al., 1993), and 
as a consequence, prolonged treatment (88 days) with exogenous testosterone causes a 
severe suppression of the hypothalamic/pituitary axis and reproductive capacity 
(Berndtson et al., 1979). In this study, testicular weight was reduced to 59% of controls 
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and spermatogenesis was impaired by a 57% reduction of sperm production; sperm motility 
was also negatively affected. Interestingly, the authors did not observe any detrimental nor 
beneficial influence of testosterone supplementation on libido.  
Data on half of stallions from the previous study, which were not castrated, were 
collected for 90 days after end of supplementation (Squires et al., 1981). Within that period, 
all of the adversely affected testicular parameters returned to values comparable to controls. 
Squires et al. concluded that the practice by the horse industry of administering androgens 
to stallions to promote libido is ineffective, at least for normal stallions. Concurring 
findings, though lacking the recovery period component, were published on anabolic-
steroids by Squires et al. (Squires et al., 1982). Administration of either boldenone or 
nandrolone for 15 weeks treatment led to reduction in LH concentrations during treatment. 
2.2.2. Immunization against GnRH 
After the first report on immunization against GnRH in a cryptorchid stallion 
(Schanbacher and Pratt, 1985), Rabb and colleagues conducted a study (Rabb et al., 1990) 
aimed at determining the effects of GnRH vaccination on relative changes in LH and FSH. 
A serial vaccination with carbodiimide-GnRH in bovine serum albumin (BSA) versus plain 
BSA, over 32 weeks, showed an anti-GnRH titer capable of reducing plasma 
concentrations of LH and FSH by 86 and 59%, respectively. Moreover, following a bolus 
injection of a GnRH analogue, immune-competent animals had a 90% reduction in LH 
response, while the FSH response to GnRH stimulation was unaffected. Even though the 
study was performed in geldings, their data provides validation on the mechanism that 
leads to decrease testosterone in the male horse through vaccination against GnRH. 
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Some pioneer studies on active immunization against GnRH specifically in the 
intact male horse were performed by Dowsett and co-workers in the early 1990’s. A 
preliminary study (Dowsett et al., 1991) was performed in pre-pubertal colts to evaluate 
the effects of an ovalbumin GnRH conjugate in mineral oil given in two injections, 11 
weeks apart. Effective antibody titer (1:1000, according to the authors) was obtained seven 
weeks after first injections, and the peak antibody response to immunization was reached 
4-5 weeks after the booster injection. Anti-GnRH titers remained above 1:1000 in 
vaccinated colts for 28-32 weeks. During this high antibody period, immunization 
prevented a testosterone rise in vaccinated colts in a comparable manner to the pre-pubertal 
colts used as controls. A testosterone rise was observed in the immunized colts 28 weeks 
from the first injection, in synchrony with the decrease in antibody titer in these colts. The 
growth rates in the colts was not affected by immunization against GnRH; however, at 17 
and 19 months, when the colts were castrated, testicular sizes in treated colts were smaller 
than controls, and morphometric evaluation showed lower Leydig cell volume. This 
indicated that reproductive function was not recovered after vaccination, at least with the 
time allowed for recovery. Lastly, there were severe reactions in the tissue injected with 
the GnRH vaccine. 
Dowsett and colleagues (Dowsett et al., 1993) pursued different modes of vaccine 
delivery and the effect of GnRH immunization in pubertal rather than pre-pubertal colts. 
Their studies involved the application of an implant formulation of the vaccine, as well as 
a water-soluble formulation, which they tested in two-year-old colts, pre-pubertal colts and 
two-year-old fillies; for this trial, only the latter group had controls. The results are 
confusing, but a high anti-GnRH antibody titer was achieved with the different forms of 
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administration and, as expected, serum testosterone concentrations were inversely 
proportional to the rise and decline in antibodies. In pubertal colts, a decline in testicular 
volume during the period of high antibody titer was reversed after the titers decreased. 
Overall, there was confusion in the publication as to what constituted the recovery period. 
In addition, there were variations in length of response to vaccine, particularly in the water-
soluble version of the vaccine, which unfortunately was the formulation resulting in least 
tissue reaction. Moreover, boosters were given as needed based on antibody titers, so 
treatment periods were not consistent, and neither were the endpoints. Therefore, this study 
did not answer the question of the time needed for recovery.  
In order to determine the optimal frequency of vaccination, a broader comparison 
of different doses of the previous studied water-soluble, ovalbumin-linked GnRH vaccine 
was pursued (Dowsett et al., 1996) once more in two-year-old colts. Similar results were 
found regarding antibody titers, which peaked 2-4 weeks after booster injection (four 
weeks after first immunization). Serum testosterone concentrations were decreased to 90 
pg/mL at six weeks after primary injection and remained suppressed (gelding levels, < 
200pg/mL) until week 31 to 43. Serum androstenedione was also decreased and reached a 
nadir concentration of 80 pg/mL at four weeks after primary vaccination and rose above 
248 pg/mL at 32 weeks after primary vaccination. During the testosterone suppression 
period, the authors failed to collect the subject stallions within a 15 min time-frame; only 
one attempt to collect semen was made while the immunity to GnRH lasted (more than 30 
weeks). Whatever change in libido reported was no longer noticed when colts regained 
normal stallion testosterone concentrations. Besides the poor effort to collect colts during 
vaccine effective period, inappropriate controls (pre-pubertal) were used and without those 
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to compare one cannot rule out factors like seasonality. Since no ejaculation was achieved 
during the high-titer / low-testosterone period, changes in sperm count could not be 
characterized throughout all of the experiment. However, total sperm number before and 
after vaccination were comparable, so if any change happened in sperm number due to 
vaccination, it seemed to be reversed at the time of the experiment. The validity of these 
finding is debatable, however, when single semen collections were compared and no 
stabilization of extra-gonadal sperm reserve was attempted.  
Later, another group of investigators (Malmgren et al., 2001) investigated the effect 
of a water-soluble BSA-conjugated GnRH vaccine with a commercially available adjuvant, 
Equimune (Vetrepharm), in mature stallions. Although methodology was explained, in 
detail, because of the small number of animals, lack of controls – data compared before 
and after vaccination – and experimental design, little can be inferred other than provide 
the descriptive findings of the study. Among three immunized 4 or 5 year old stallions, one 
failed to develop satisfactory GnRH antibody titer: peak of 10% binding capacity at 1:6400 
dilution compared to 70 % and 80% in the other two, even when all of the stallions received 
four booster injections after the first, at two or four week intervals. Testosterone and 
estrone sulphate concentrations were reduced to castrate levels (<129 pg/mL and <1.46 
ng/mL, respectively) during the high titer period of the two responding stallions (starting 
four weeks after first injection). Sexual behavior seemed to be affected, though some of 
the evaluations (e.g. handleability) were subjective, while the objective parameters 
(elapsed time for ejaculation and number of mounts per ejaculation), could have been 
affected by seasonality and were not properly compared to control values. Sperm 
production, sperm motility and sperm morphology were affected in stallions carrying high 
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titers against GnRH; likewise testicular size. Parenchymal alterations due to immunization 
seemed to involve lipid droplet accumulation in the Leydig cells; degeneration of Sertoli 
and germ cells and scarce number of spermatids and spermatocytes. There was local tissue 
reaction to the vaccine in all treated stallions, especially those with high titers. The stallions 
were only followed for 3 weeks after the last injection, so no inferences can be made on 
reversibility of the effects of immunization since the study was not designed for that. 
Because of tissue reactions to the GnRH vaccine, and because of inconsistency in 
response to vaccination, another study was conducted in mature (four-year-old) pony 
stallions (Turkstra et al., 2005). A tandem GnRH dimer conjugated to ovalbumin in PBS 
was tested using two different adjuvants: CoVaccineTM HT or Carbopol). The former 
adjuvant proved efficacious in all subject stallions in inducing antibody titers with 56-76% 
binding at 1:2000 dilution. This high titer was achieved by two weeks after booster 
vaccination, six weeks after the initial immunization, and decreased testosterone levels for 
six weeks (until the end of experiment). It also decreased motility of sperm in 3 of 4 
stallions treated with the formulation. The authors reported a reduction in testis size, as 
well as reduced seminiferous tubule diameter, absence of tubular lumen and reduced 
number of tubules with elongating spermatids and spermatozoa, which indicated severe 
effects on spermatogenesis. Though the study was not designed to evaluate effects on 
libido, failure to ejaculate was recorded in one stallions for each vaccine form. Finally, 
injection site reactions were not reported regardless of the titer achieved by immunization, 
although antibody titers depended on the type of adjuvant used. 
Another report (Clement et al., 2005), based upon the CoVaccineTM HT adjuvanted 
immunization, described a decrease in testosterone in half of subject stallions. Testosterone 
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concentrations were recovered within six months after the last booster. No effect on libido, 
time for erection, time for ejaculation or number of mounts was seen in any of the stallions. 
The effects on total testes width and semen parameters including total sperm number, 
morphologically abnormal sperm and sperm motility were noticed in some but not all 
stallions. Recovery in sperm motility did not occur in all stallions. Interestingly, although 
the study did not target EAV shedding stallions, one of the stallions that responded well to 
vaccination was an EAV carrier stallion; 6 weeks after first vaccination the stallion’s semen 
was virus negative; however, semen were EAV positive at two months after the last 
vaccination. 
Burger (Burger et al., 2006) reported on  the effects of two commercial vaccines, 
Equity® or Improvac®, on sexual behavior, semen quality, testis size and EAV shedding 
state in adult stallions. In the first experiment, using Equity®, vaccinated stallions showed 
a reduction in testosterone concentrations under 200pg/mL, but by 30 weeks from the last 
vaccine booster, some stallions still had not regained pre-treatment testosterone values. 
Antibody titers remained high (value not disclosed) until the end of the experiment. Libido 
was affected (parameters no disclosed) with individual variation; scrotal size, total sperm 
number, morphologically normal sperm and motility were decreased after vaccination and 
tended towards pre-vaccination values 10-12 months after the beginning of the study. A 
second experiment consisted of a questionnaire based on a field study in which vaccines 
were given to stallions of various breeds, with a booster 28-35 days after first vaccination. 
Seventeen out of nineteen stallions with behavioral issues responded with the desired 
decrease in libido. Endpoints involved subjective parameters such as distraction level and 
aggressiveness towards humans. A third experiment consisted of vaccination of four EAV 
 
22 
long-term carrier stallions. The virus could no longer be isolated from ejaculates of the 
stallions 6 months (as long as subjects were monitored) after the first vaccination (booster 
was given 4 weeks later). One stallion died 6 ½ months after first vaccination, but, 12-17 
months after the 1st vaccination, the remaining stallions were each bred to two mares, which 
failed to seroconvert the virus within 28 days after breeding. The published abstract lacked 
statistical analysis, important details, non-vaccinated EAV-carriers as controls and had 
subjective evaluation of endpoints. Accordingly, discretion should be exercised if 
extrapolate from these results. It was, nonetheless, a study designed to evaluate anti-GnRH 
vaccination in order for eliminating the EAV carrier state in stallions. 
More recently (Janett et al., 2009), the commercial vaccine, Equity®, was tested in 
sexually mature stallions (6-15 years old) for its effect on testicular function and sexual 
behavior. After receiving three immunizations at four and eight week intervals, the stallions 
were monitored weekly for a year. One of five stallions failed to develop antibody titers 
above 15 % at a 1:40 dilution, compared to the 30-44% peak binding found in the remaining 
four animals. In the vaccinated stallions, peripheral testosterone, sperm motility and 
morphologically normal sperm were decreased, except for the one stallion with a low 
anybody titer. Four of the immunized stallions presented changes in libido (elapsed time 
to achieve erection and ejaculation), and during the suppression period, four of five 
stallions failed to ejaculate in a 10 minute time-frame, while that trend was not seen in the 
controls. Resumption of reproductive activity was not seen in two of the subjects, whose 
testosterone concentrations did not return to normal; one stallion had a prolonged decline 
in sperm count, and another could not be collected. In this study, only minor reactions at 
injection sites were reported. 
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Based on available reports, thus far no GnRH vaccine was able to both generate 
adequate anti-GnRH titers and permit full recovery of testicular function. It appears that 
sexual behavior is affected, but not in all of the subjects, neither is libido recovered in all 
stallions that were affected. Were found in mares similar results regarding the effects of 
immunization against GnRH on behavior and gonadal activity. Ovulatory function and 
display of estrous behavior failed to resume to normality (Imboden et al., 2006; Elhay et 
al., 2007), even after recovery periods longer than 90 weeks (Imboden et al., 2006). This 
may serve as an illustration of the prolonged effects of immunization against GnRH in the 
equine species. 
2.2.3. GnRH agonists 
Since 1972, soon after the molecular structure of mammalian GnRH was 
characterized, work was undertaken to synthesize analogs of GnRH. The half-life of GnRH 
is very short – about 2-4 min – and more potent and longer-acting analogs were considered 
more suitable for many of the clinical applications in humans. Various amino acid 
replacements to the original decapeptide GnRH sequence were shown to increase 
resistance to enzymatic degradation of the molecule and to enhance receptor affinity. For 
instance, substitutions at positions 6 and 10 can lead to superactive peptides, such as 
Buserelin, (Schally, 1999), which may be 20-100 times more potent than native GnRH 
(Clayton and Catt, 1980; Conn and Crowley, 1991; Schally, 1999). 
Although a single injection of superactive agonists of GnRH induced a sustained 
release of FSH and LH, repeated administration produces inhibitory effects (Schally, 
1999). In various species, the continuous exposure of the anterior pituitary to high doses 
of GnRH or to potent analogues of GnRH leads to a non-responsive state (Fraser, 1982). 
Continuous stimulation of the pituitary by prolonged administration of GnRH or its 
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superagonists inhibits the hypophyseal-gonadal axis through down-regulation (a reduction 
in number) of pituitary receptors for GnRH, decreased gene expression, desensitization of 
pituitary gonadotrophs and suppression of circulating levels of LH and sex steroids 
(Schally, 1999).  
In humans, important clinical applications from sustained administration with 
GnRH agonists include treatment for central precocious puberty, polycystic ovarian 
disease, benign prostatic hyperplasia, endometriosis and others. Also, therapy for sex 
hormone dependent malignant neoplasms in women (e.g. breast cancer, endometrial 
carcinoma) and men (e.g. prostate cancer) is based on the reversible medical castration and 
the creation of a state of sex steroid deprivation (Schally, 1999). In domestic species, it has 
been demonstrated that prolonged GnRH agonist treatment can induce an antagonistic 
effect over time in rams (Bremner et al., 1976), male dogs (Vickery et al., 1984), boars 
(Kauffold et al., 2010), bulls (Godfrey et al., 1989) and others (Fraser, 1982).  
Much of the reluctance by clinicians and researchers to pursue GnRH therapy for 
stallions for agonistic purposes, in particular sub-fertile ones, came from data in other 
species and inconsistent results in horses (Brinsko, 1996; Brinsko et al., 1998). A case 
report provided data in which an infertile stallion, subject to treatment with daily GnRH 
for 5 months had its sperm numbers and motility increase then stabilize throughout the 
breeding season (Evans and Finley, 1990). On the other hand, an uncontrolled study 
provided data that a 30-day treatment with GnRH tended to reduce testosterone 
concentrations in two of three stallions, though it did not induce any beneficial or 
detrimental changes in sperm numbers nor libido. In the same study, a 35-day long GnRH 
treatment in mares appeared to decrease ovarian activity (Montovan et al., 1990). Data 
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from Blue et al. showed that GnRH administration from February to July, in continuous or 
pulsatile manner did not change LH and testosterone concentrations, scrotal width, total 
sperm per ejaculate or sperm motility. Pulsatile administration of GnRH was not able to 
improve seminal and testicular parameters in abnormal stallions, in which they were 
inherently decreased (Blue et al., 1991).  
It seems that the only study to show that prolonged GnRH treatment could clearly 
down-regulate testicular function was that of Boyle and colleagues, in which implants of 
the potent GnRH analog, Buserelin, were administered for a period of 12 months. This 
treatment led to a 50% decrease in DSO compared to controls. FSH, LH, testosterone and 
estrone sulphate concentrations were suppressed but these fluctuated and not all of the 
treated stallions demonstrated the same level of suppression. No changes were seen in 
libido throughout the 12 months compared to controls (Boyle et al., 1991). The authors 
reported that 7 months after the last implant was injected, all parameters had returned to 
normal values in the treated stallions. 
 It seemed that only prolonged treatment with high doses of GnRH would achieve 
down-regulation of the HPG axis in the stallion when given in a continuous manner. In 
fact, data from mares showed that suppression of LH occurred after continuous 
administration of GnRH, but not after pulsatile administration. Neither treatment affected 
follicular development or time for ovulation (Becker and Johnson, 1992). Thus, Brinsko 
designed a study to evaluate the effect of  pulsatile administration of high doses of GnRH 
(250µg) for 75 days to stallions. No reduction was reported in LH, FSH or testosterone. 
On the contrary, concentrations of gonadotropins and testosterone increased during the 
treatment period in stallions receiving GnRH. Brinsko and colleagues concluded that the 
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HPG axis of the stallion is remarkably resistant to down-regulation following 
administration of exogenous GnRH in comparison to other species (Brinsko et al., 1998).  
More recently, data supporting the beneficial effects of GnRH therapy in stallions 
was published by Sieme and collaborators (Sieme et al., 2004), who administered the 
agonist Buserelin 50µg twice daily for 6 weeks in the non-breeding season. Treatment 
increased libido parameters, as well as sperm motility, membrane integrity and 
functionality. It also reduced the detrimental effects of freezing on progressive motility. 
Only a few publications illustrate the clinical improvement on sperm quantity and 
quality by GnRH treatment in stallions; the response depends upon the appropriate form of 
GnRH, delivery manner, dose and length of treatment to achieve improvements on 
reproductive function. On the other hand, the available evidence shows that down-
regulation of the HPG axis in the male horse does not match that of other species in that 
the horse is unusually resistant to refractoriness (Brinsko, 1996); which precludes the 
clinical use of GnRH to diminish libido, decrease circulating testosterone or other desired 
effect on reproductive function by down-regulation of GnRH. 
2.2.4. GnRH antagonists 
Comprehensive reviews (Karten and Rivier, 1986; Rivier et al., 1996)  have been 
published on the historical advances and molecular modifications to native GnRH that lead 
to antagonist molecules of clinical applicability. 
The first antagonist to GnRH was reported in 1972 (Vale et al., 1972). The work in 
creating such peptides started concomitantly with development of agonists. Due to 
requirement for high affinity (without stimulatory activity) and resistance to enzymatic 
degradation, the design of GnRH antagonists was slow. Small, incremental increases in 
potency and duration of effect were reported from time to time and appeared in the 
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literature as equipotent groups of GnRH antagonists (Karten and Rivier, 1986). At first, 
GnRH antagonists were of very low potency relative to GnRH, which resulted in large 
doses required to be used both in vitro and in vivo (Karten and Rivier, 1986; Behre et al., 
1998). Furthermore, as the potency in vivo increased with new amino acid replacements in 
positions 2, 3 and 6 of the GnRH molecule, these antagonists, triggered histamine release 
from mast cells in the circulation, which caused side effects ranging from local erythema 
to general edema and decrease in blood pressure which rendered these antagonists 
unacceptable for clinical purposes. A second-generation of GnRH antagonists had further 
structural modifications to the polypeptide chain of GnRH, at positions 5 and 6. This 
change led to similar or higher potency but lower histamine release, and no systemic side-
effects, though the high doses needed for clinical use still provoked local side-effects 
(Behre et al., 1998). The so called third-generation antagonists had modifications on up to 
6 or 7 amino acids of the decapeptide chain of GnRH making available antagonists of even 
higher potency (Behre et al., 1998; Schally, 1999). The modifications also decreased 
histamine effects of these antagonists to minor or negligible local side-effects, and hence 
were deemed safe for clinical applications in humans. The antagonists Cetrorelix and 
Ganirelix were both approved by the FDA for certain applications. 
The mechanism of action of the GnRH antagonists is primarily by competitive 
blockade of the GnRH receptor in the gonadotrophs, precluding substantial occupation 
(and stimulation) by endogenous GnRH (Conn and Crowley, 1991; Schally, 1999; Huirne 
and Lambalk, 2001) resulting in immediate inhibition. This is in contrast to GnRH agonists, 
which require repeated administrations to achieve this effect. It has also been shown that 
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down-regulation of GnRH receptor numbers (Behre et al., 1997) and of GnRH receptor 
mRNA (Pinski et al., 1996) may occur following GnRH antagonist treatment. 
GnRH antagonists have similar clinical applications as GnRH agonists with down-
regulation as the aim (Schally, 1999; Huirne and Lambalk, 2001), though one advantage 
of the antagonist is the absence of a transient stimulatory effect. The lack of stimulation 
(which happens with GnRH agonists) before down-regulation has application to avoid 
premature LH surge in IVF programs in women (Fluker, 2000; Ron-El et al., 2000; 
Fasouliotis et al., 2003) and, more importantly, avoids a clinical “flare-up” that may happen 
in men treated with GnRH agonist for prostate cancer, in which a transient testosterone 
surge could reflect that metastasis has occurred (Schally, 1999; Huirne and Lambalk, 2001; 
Weckermann and Harzmann, 2004; van Poppel and Nilsson, 2008).  Furthermore, in the 
case of antagonists versus agonists, the course of treatment tends to decrease, and a more 
rapid and predictable recovery is possible after cessation of treatment with antagonist 
(Rivier et al., 1996). 
Even though less than a handful of antagonists are FDA approved for use in humans 
there are different compounds under trials and the veterinary scientific literature reports 
the successful use of antagonists on down-regulating the HPG axis for various purposes in 
domestic carnivores (Gobello, 2012), ruminants (Gonzalez-Bulnes et al., 2005; Jimenez-
Severiano et al., 2007) and pigs (Patterson-Bay et al., 1997; Zanella et al., 2000) with 
reversibility seen in most of the trials where it was assessed. 
In horses, follicular development and ovulation was investigated in mares after the 
treatment with GnRH antagonist. Watson and colleagues (Watson et al., 2000) found that 
Antarelix successfully down-regulated the pituitary and ovarian activity in cyclic mares. 
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The antagonist, administered on day 8 after ovulation, caused a fall in progesterone the 
next day, delayed estradiol and LH surges in the cycle, as well as increased the inter-
ovulatory interval, though not compromising the timing of luteolysis. Later, studies of 
Briant (Briant et al., 2003; Briant et al., 2004) utilized the antagonist Antarelix to suppress 
pre-ovulatory LH surge in mares with the aim of studying the timing of ovulation. 
Reports on the use of GnRH antagonists in stallions are limited. An uncontrolled 
study by Hinojosa et al. (Hinojosa et al., 2001) reported the effects of a single injection of 
the GnRH antagonist Antarelix in pony stallions of 2-5 years of age. Plasma concentrations 
of LH, FSH and estradiol were significantly decreased within 48h of the treatment injection 
and returned to pretreatment values by 4 to 6 weeks after treatment. No changes were seen 
in circulating testosterone, sperm motility or morphology, though an increasing number of 
round spermatogenic cells was noticed. Libido seemed to be affected by the single 
injection, but the authors suggested that it might have been confounded by paired stabling 
of stallions and distance from mares.  
An abstract report in 2002 described the use of Antarelix or Cetrorelix in EAV 
carrier stallions (Fortier et al., 2002). For this trial, the dose was increased to twice daily 
(100ug/kg) compared to a single dose in the aforementioned studies and was given for 35-
38 days. In treated stallions, testosterone decreased to basal levels within one week, except 
for one stallion, then returned to pre-treatment values at one week after the end of 
treatment. There was a transient decrease in the quantity and quality of semen produced. 
Those parameters appeared to be reduced the most by 22 to 55 days after the end of 
treatment, and were restored to normal levels by 75 to 110 days after end of treatment. The 
effects on the EAV carrier state was variable among stallions and treatment groups. All of 
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the treated stallions became semen negative for EAV on semen isolates before the end of 
treatment, although one stallion assigned for treatment group spontaneously cleared just 
before starting treatment. There was spontaneous clearing of virus in the semen of some of 
the control stallions, while some treated stallions that became non-shedders during 
treatment recommenced shedding between 14 and 42 days later. Results were confounded 
by the high number of stallions that spontaneously cleared. Some treated stallions which 
had become EAV negative reverted to an EAV positive state after cessation of treatment, 
which does not occur in spontaneous cessation of shedding (see section 2.2.1). Therefore, 
the occurrence momentary clearing of viral load in ejaculates after treatment suggests a 
causal relationship between the GnRH antagonist treatment and the viral status of the 
stallions. 
A. Third-generation antagonist, Acyline 
Acyline, first described by Rivier et al. (Rivier et al., 1995), is a member of azaline 
family of third-generation antagonists; it is a decapeptide like GnRH, but has modifications 
in amino acids 1, 2, 3, 5, 6, 8 and 10 [Ac-D-Nal-D-4-Cl-Phe-D-Pal-Ser-Aph(Ac)-D-
Aph(Ac)-Leu-Lys(Ipr)-Pro-D-Ala-NH2]. Acyline resulted from attempts to increase 
hydro-solubility and decrease gel formation while retaining potency by introducing 
betidamino acids (Jiang et al., 1997). These are amino acids in the beta position, presenting 
acyl groups which probably explains the assigned name of the drug. 
Acyline has been used to interfere with the effects of GnRH in rodents (Jiang et al., 
1997), cattle (Ginther et al., 2011), cats (Garcia Romero et al., 2012a), as well as men and 
dogs. In some trials in men, acyline was shown to be very potent in decreasing circulating 
gonadotropins and testosterone. In the first report of administration of acyline in men, 
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administration of 75 µg/kg of acyline resulted in a seven-day suppression of peripheral 
testosterone, reaching a nadir at 48h, though a decline in testosterone concentration 
occurred already within 15h. Acyline produced a longer down-regulation of the HPG axis 
compared to Cetrorelix, which reaches a nadir in testosterone suppression at 12h with a 
return to baseline values at 48h (Herbst et al., 2002). In a subsequent trial, a single injection 
of the acyline (300 µg/kg) reduced gonadotropin and testosterone concentrations to those 
of castrates (in men, below 1.45 ng/mL) for 17 days, and these hormones remained below 
values of controls for 19 days, returning to baseline values at day 21 (Herbst et al., 2004). 
A more recent study showed potential applications for the use of acyline orally, which is 
unusual for GnRH antagonists since these peptides cannot endure the low pH of the 
stomach (Amory et al., 2009). The oral version, at doses of 20 and 40 mg, promoted and 
sustained suppression of testosterone for 12-24h, with return to basal levels at 48h. 
 In male dogs, a single dose of acyline (330µg/kg) decreased gonadotropin and 
testosterone concentrations for at least nine days (Garcia Romero et al., 2009). Acyline 
also decreased libido and erectile function for four weeks, and sperm numbers for six weeks 
(Valiente et al., 2007). Two of the seven treated dogs became azoospermic during weeks 1 
and 2, and four of the treated dogs showed azoospermia at week two after administration 
of acyline. In this study an increase in round spermatogenic cells was observed at week 
four after injection but values decreased to control values from week six to 8. Although 
libido and erection recovered during the follow up, full recovery of seminal parameters 
was not observed in this study, which the authors attribute to a short recovery period. In a 
later study (Garcia Romero et al., 2012b), acyline prevented the canine gonadal axis from 
responding to an exogenous GnRH agonist; such challenge was performed serially with 
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the superagonist Buserelin. Circulating testosterone in acyline treated dogs was not 
incremented by GnRH stimulation. The length of testosterone suppression after a single 
acyline injection did not differ due to the exogenous GnRH stimulations when compared 
with the single-injection treatment without GnRH stimulations (Garcia Romero et al., 
2009). 
To our knowledge, the only published studies on the use of acyline in the horse 
were performed in mares (Checura et al., 2009; Checura et al., 2010). Instead of a long 
lasting down-regulation of the HPG axis, these studies sought a short blockade of GnRH 
activity with a low dose of acyline (maximum of 3mg, single dose) to investigate 
interactions of the antagonist with FSH release and follicular development. Such treatment 
was enough to decrease circulating concentrations of FSH of mares after FSH-increasing 
stimuli such as follicular ablation and exogenous GnRH administration and to retard 
growth of the dominant follicle when given right before deviation. 
Data from our lab (not published) suggests that two injections of acyline (50mg in 
5% mannitol solution) given 10 days apart were enough to increase inter-ovulatory 
intervals in cycling mares. 
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Chapter Three:                                                                                                    
Reversible downregulation of hypothalamic-pituitary-gonadal axis in the stallion 
with a GnRH antagonist 
3.1. Introduction  
Methods to suppress the hypothalamic-pituitary-gonadal (HPG) axis in stallions with 
resultant suppression of androgen and estrogen production have been examined for 
different reasons including: (1) elimination of the carrier state in equine arteritis virus 
(EAV) persistently infected stallions and (2) alteration of sexual/aggressive behavior. Over 
the last decade, equine viral arteritis (EVA) outbreaks on different continents reemphasize 
the important epidemiologic role that persistently infected carrier stallions play in the 
dissemination EAV through infective semen (Timoney et al., 1986; Timoney et al., 1987; 
Timoney et al., 2006; Barrandeguy, 2010; Pronost et al., 2010; Miszczak et al., 2012). After 
resolution of the acute phase of the, 30 to 60% of stallions may become persistent carriers 
of EAV and shed the virus in their semen (Neu et al., 1987; Timoney and McCollum, 
1993). Persistent infection with EAV is androgen dependent (Little et al., 1991; Holyoak 
et al., 1993; McCollum et al., 1994) and removal of endogenous testosterone results in 
termination of the persistent carrier state (Little et al., 1991). Castration, on its turn, has 
been historically the method of choice to deal with stallions that present excessive display 
of sexual or aggressive behavior. Orchiectomy seems to solve most of the cases in which 
such behavior may compromise performance of colts during training or competition (Line 
et al., 1985). However, surgical castration precludes the use of stallions for breeding after 
retirement from a successful sports career.  
As an alternative to castration, several approaches have been investigated to 
downregulate the HPG axis in the stallion, including treatment with altrenogest and 
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immunization against GnRH as well as downregulation of pituitary GnRH receptors with 
GnRH agonists and antagonists. Off-label use of altrenogest in training or competing 
stallions is very common (Goolsby et al., 2004), although recovery from a decline in libido 
and various reproductive parameters after treatments longer than eight weeks has not been 
demonstrated (Squires et al., 1997; Johnson et al., 1998). There are also regulations to limit 
the use of altrenogest in certain countries – e.g. European Union – where the horses may 
be considered a food animal. Immunization against GnRH to achieve a reduced activity of 
this hormone has been used in pigs and ruminants to avoid surgical castration (Adams and 
Adams, 1992; Dunshea et al., 2001). Immunization against GnRH has also been 
investigated in stallions (Dowsett et al., 1996; Malmgren et al., 2001; Turkstra et al., 2005; 
Janett et al., 2009), including its use as a potential treatment for EAV carrier stallions 
(Burger et al., 2006). Nonetheless, at least four weeks are required for adequate anti-GnRH 
titers to be produced after the first immunization and resumption of reproductive function 
is not regained by all of the treated stallions, in which suppression of libido and serum 
testosterone may persist indefinitely (Burger et al., 2006; Janett et al., 2009).  
Even though in men and most domestic animal species prolonged, repeated 
stimulation of GnRH receptors with high doses of GnRH or potent analogs cause down-
regulation of pituitary gonadotrophs and decreased LH and FSH release after a transient 
stimulatory effect (Bremner et al., 1976; Fraser, 1982; Vickery et al., 1984; Godfrey et al., 
1989; Schally, 1999; Huirne and Lambalk, 2001; Kauffold et al., 2010), the stallion appears 
to be  resistant to down-regulation by exogenous GnRH agonists (Blue et al., 1991; Boyle 
et al., 1991; Brinsko, 1996). However, GnRH antagonists, which lead to direct inhibition 
rather than activation of the GnRH receptor (Heber et al., 1982; Karten and Rivier, 1986; 
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Rivier et al., 1996), have been shown in a few reports to be effective in stallions. A study 
by Hinojosa and colleagues (Hinojosa et al., 2001) reported that a single injection of GnRH 
antagonist, Antarelix, in pony stallions induced a decrease of plasma gonadotropins and 
estradiol. Even though Antarelix administration did not decrease in testosterone, libido 
seemed to be affected. The use of Antarelix and a second GnRH antagonist, Cetrorelix, 
daily for 35 to 38 days in EAV carrier stallions (Fortier et al., 2002) achieved a reversible 
decrease in testosterone and a transient reduction in sperm number and quality. However, 
treated stallions resumed virus shedding status after momentarily clearing the virus during 
treatment. This suggested a causal relationship between GnRH antagonist treatment and 
the viral status of the stallions because resumption of virus shedding is not seen in stallions 
that spontaneously clear the virus (Timoney and McCollum, 1993; 2000) 
A potent third-generation GnRH antagonist, acyline [Ac-D2Nal-D4Cpa-D3Pal-
Ser-4Aph(Ac)-D4Aph(Ac)-Leu-Lys(Ipr)-Pro- DAla-NH2], was described in 1995 (Rivier 
et al., 1995). Initial trials in men have shown that acyline decreases FSH and LH for 15 to 
20 days, and acyline reduces testosterone to castrate levels for 2 weeks after a single 
injection of 300 µg/kg (Herbst et al., 2004). In male dogs, a single dose of acyline (330 
µg/kg) decreased FSH, LH and testosterone concentrations for at least nine days (Garcia 
Romero et al., 2009). Dogs treated with acyline had reduced sperm numbers for six weeks 
and severely reduced libido and erectile function for four weeks. Although recovery from 
effects on semen were not seen in the eight-week follow-up, libido and erection capability 
recovered during this period (Valiente et al., 2007). A more recent study showed that 
acyline prevented the canine HPG axis responding to repeated challenges with the 
superagonist, Buserelin (Garcia Romero et al., 2012b).  
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Although there are no reports of acyline administration to stallions, acyline 
(approximately 10 µg/kg) was utilized in pony mares (Checura et al., 2009; Checura et al., 
2010) to investigate interactions of the antagonist with FSH release and follicular 
development. Acyline blockade of GnRH activity in mares decreased circulating 
concentrations of FSH and retarded growth of the dominant follicle.  
In the current study, we hypothesized that acyline administration results in down-
regulation of the HPG axis in stallions and that, in addition, the effects of such blockade 
would be reversed after the end of treatment. The objectives of this study were to (1) 
determine the effects of acyline treatment on changes in endocrine, seminal, behavioral and 
testicular volume parameters of stallions; (2) determine responsiveness of acyline-treated 
stallions to GnRH stimulation; and (3) to examine recovery of these parameters after 
withdrawal of acyline treatment. 
3.2. Material and methods 
A. Animals 
All animal experimentation was conducted according to a protocol approved by the 
Institutional Animal Care and Use Committee at the University of Kentucky (#2011-0854). 
Eight light-horse stallions (3-15 years, median = 9) were housed in individual box stalls at 
Maine Chance Farm (University of Kentucky, Lexington, KY). Stallions received hay and 
water ad-libitum in addition to combined whole oats and commercial concentrate (0.4% 
BW), and stallions had access to salt and mineral sources. Stallions were turned out into 
small fenced paddocks (at least 5 d a week) with visual contact with mares in nearby 
pastures.  
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B. Acyline dose determination 
A preliminary study was conducted to compare the effect of two different doses of 
acyline on serum testosterone concentrations. Stallions (n=2, not included in the main 
study) received either 100µg/kg or 330 µg/kg acyline in 5% mannitol as a single 
intramuscular administration, and blood was collected daily for 10 d for determination of 
serum testosterone concentrations. Based upon this preliminary study, a dosage of 330 
µg/kg at 5-d intervals was chosen for the main experiment. 
C. Experimental design 
To establish pre-treatment baseline seminal parameters, stallions had semen 
collected daily (Monday – Friday) for two weeks. Testis volume was measured weekly via 
ultrasonography. Daily sperm output (DSO) was estimated based upon the total number of 
sperm collected on the fifth day of semen collection each week as previously described 
(Thompson et al., 2004). Stallions were matched based on DSO (average of pre-treatment 
weeks), testicular size and age, then were randomly assigned to treatment (n=4; acyline 
330µg/kg q 5d, IM) or control (n=4; 10mL vehicle, q 5d, IM) groups. The treatment period 
was 50 days, and the recovery period was 72 days after last treatment. The experiment was 
conducted from mid-August through mid-December in the Northern Hemisphere.  
D. Endocrine evaluation 
Jugular blood samples were obtained in the morning prior to feeding and to acyline 
treatment, in days administered (~7AM). Blood was collected in heparinized tubes (BD, 
Franklin Lakes, NJ), and plasma was separated by centrifugation at 2500 xG for 10 min at 
4oC. Thereafter, plasma samples were frozen and stored at -20oC until analysis. 
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Plasma testosterone and estrone sulfate concentrations were determined daily for 
the last five days pre-treatment and the first nine days of treatment; then, on the days of 
treatment administration (q 5d), and two days following each treatment administration 
through the end of treatment. During the recovery period, plasma steroid concentrations 
were determined once weekly. Testosterone was determined using a competitive ELISA. 
A standard curve with a range from 0.02 ng/mL to 10 ng/mL was used with a limit of 
detection of 40 pg/mL (Esteller-Vico, 2015). Estrone sulfate was analyzed using a 
previously described competitive ELISA (Carneiro et al., 1998). Samples were run in 
triplicates. Intra- and inter-assays coefficients of variation (CV) for testosterone were 13% 
and 11% (low-binding = 10%; high-binding = 12%), respectively. Estrone sulfate intra-
assay CV was 11% and inter-assay average was 11% (low-binding = 7%; high-binding = 
14%).  
Follicle-stimulating hormone, (FSH) and luteinizing hormone (LH) assays were run 
on days -3, 0 to 7, 17, 32, 52, 53, 56 to 59, 73, 87, 101 and 112 relative to treatment (day 0 
= day of initial treatment). Follicle-stimulating hormone and luteinizing hormone were 
determined by the heterologous double-antibody RIA method (Roser and Hughes, 1991). 
Sensitivity was 0.25 ng/mL for both gonadotropins, and the intra-assay CVs were 2.72% 
for LH and 2.46 for FSH, each run in a single assay.  
Gonadotropin-releasing hormone stimulation tests were performed prior to the 
beginning of treatment and during the seventh week of treatment in order to evaluate the 
suppression of the hypothalamic-pituitary-gonadal axis. The procedure consisted of 
injecting 25µg of GnRH (IV, gonadorelin diacetate tetrahydrate; Cystorelin, Merial LLC, 
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Duluth, GA). Blood was collected 30 min before, immediately prior to and 30, 60 and 120 
min post GnRH administration (Roser and Hughes, 1992). 
Plasma anti-Müllerian hormone (AMH) concentrations were determined using a 
commercially available ELISA (AMH ELISA, MOFA Global, Verona, WI) per the 
manufacturer’s instructions. Plasma AMH concentrations were determined weekly from 
day -6 to 87 relative to the beginning of treatment. 
E. Semen collection and evaluation 
Semen collections were performed Monday through Friday for two weeks after 
onset of treatment, and then on alternate weeks until the end of the experiment. Only the 
fifth daily ejaculate for that week (i.e., DSO ejaculate) was used for semen evaluation data. 
Stallions were brought into the breeding shed and exposed to an estrogen-primed 
ovariectomized mare (estradiol cypionate [BET Pharmacy, Lexington, KY] 10mg, q 7 d, 
IM). The stallion was teased until an erection was obtained, the penis was washed with 
warm water, and the stallion was allowed to mount a phantom for semen collection with a 
Missouri model artificial vagina. 
The gel portion of ejaculates was removed by filtration, and the gel-free volume 
was determined by weight (1g = 1mL). Sperm concentration was obtained with a 
densimeter (591B densimeter, Animal Reproduction Systems, Chinoe, CA). Total motility, 
progressive motility and other sperm motion characteristics were obtained with computer-
assisted sperm analysis (CASA; SpermVision, MOFA Global, Verona, WI). Preparation 
of samples for motility analysis consisted of diluting a fraction of ejaculate with a skim-
milk extender (EquiPRO, MOFA Global, Verona, WI) to a final concentration of 30x106 
sperm/mL. Eight microliters of extended sperm suspension were placed on a microscope 
 
40 
slide (22x22-2 mm coverslip), at 37oC and allowed to stabilize for at least 30 sec before 
acquiring the data. The settings of the CASA were as follows. Level 1 cell classifications: 
immotile = AOC (average orientation change of the head) <7; locally motile = DSL 
(distance straight line) <6. Level 2 classifications: hyperactive= VCL (velocity curved line) 
>8, LIN (linearity) <0.65 and ALH (amplitude lateral head displacement) >6.5; linear= 
STR (straightness) >0.9 and LIN>0.5; non-linear= STR<0.9 and LIN<0.5; curvilinear= 
DAP (distance average path)/radius ≥3 and LIN<0.5. Cell identification was set for an area 
of 14 to 80µm2. Motility assessment was repeated with a minimum of 7 fields or 500 cells.  
Aliquots for sperm morphology assessment consisted of 50 µL of raw semen fixed 
in 1mL 10% buffered formalin. Subsequent evaluation was performed in wet mounts under 
DIC microscopy (Axio Imager 2, Carl Zeiss Microscopy LLC, Thornwood, NY) at 900x 
magnification. Seminal plasma from ejaculates collected on Tuesdays and Thursdays was 
obtained by centrifugation at 2000 x g for 10 min, and stored at -20oC until analysis. 
Osmolality of seminal plasma was determined by osmometry (Micro Osmette, Model 5004 
Automatic Osmometer, Precision Systems, Natick, MA). Protein concentration in seminal 
plasma was determined with comassie (Bradford) protein assay kit (#23200, Thermo 
Scientific, Kalamazoo, MI, USA) as previously described (Bradford, 1976).  
F. Testicular volume 
Weekly testicular measurements were taken throughout the study. Stallions were 
placed in stocks and sedated (100-150 mg xylazine, [AnaSed, Lloyd, Shenandoah, IA], 
IV). The height, width and length of individual testes were determined with B-mode 
ultrasonography (Sonoscape S8, Universal Medical Systems Inc., Bedford Hills, NY), and 
values were recorded as the average of three measurements. Ultrasonographic 
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measurements and the estimation of testis volume was performed as described by Love 
(Love et al., 1991). 
G. Reproductive behavior 
Data on breeding behavior and libido recorded for each stallion included time from 
entrance into the breeding shed until erection and ejaculation as well as the total number 
of mounts per ejaculation. If a stallion failed to mount the phantom within 10 min, the tease 
mare was positioned beside the phantom for additional stimulation. A total time of 15 min 
was allowed for the stallions to show interest in the mare, mount the phantom and ejaculate. 
Failure to ejaculate in that time frame was recorded as a failure of collection and data 
regarding time to erection and ejaculation were not included in the dataset; however, a 
continued attempt was still made to obtain the ejaculate for other data points. At least two 
different tease mares were available throughout the experiment.  
3.3. Statistical Analysis 
Continuous data were analyzed using a random-effects mixed model (JMP, ver. 
10.0; SAS Institute; Cary, North Carolina, USA) with treatment and time as fixed effects 
and stallion as a random effect. Where necessary, data were log transformed, and model 
assumptions were evaluated using normal quantile plots of residuals. Data are presented as 
untransformed means ± S.E.M. Comparisons between treatment groups at individual time 
points were made using the test-slice function of JMP to generate preplanned linear 
contrasts. Changes in LH, FSH and testosterone subsequent to GnRH stimulation were 
evaluated as area-under-the-curve (AUC) using a random effects mixed model with 
treatment and period (pre- vs during-treatment) as fixed effects and stallion as a random 
effect; that was followed by comparison of least square means of the AUCs in a Tukey’s 
 
42 
test. Round cell numbers were compared with a Wilcoxon/Kruskal-Wallis test. Osmolality 
and protein content of seminal plasma (two observations per week of collection) were 
assessed based upon the weekly mean value. Behavior parameters were evaluated as 
weekly averages. 
3.4. Results 
A. Endocrine Parameters 
For all data presented, days are presented relative to the initiation of treatment (Day 
0). Plasma FSH concentrations in acyline-treated stallions were less than controls at day 
17 and day 32 of treatment (p < 0.05), and FSH was lower in the treatment group at days 
6, 7, 8 and 9 after the cessation of treatment (Fig 1). FSH concentrations in the treated 
stallions were greater than control stallions at days 37, 51 and 62 after the cessation of 
treatment (Fig. 1). Plasma LH concentrations declined by day 2 after treatment, and 
concentrations were lower than controls throughout treatment measured time-points except 
for days 3 and 4 (p < 0.05). Concentrations of LH displayed a rebound during the recovery 
period as shown by a higher (p < 0.05) LH concentration on day 37 after the end of 
treatment in the acyline-treated stallions (Fig. 2).  
There was a significant time (P < 0.001) and time-by-treatment interaction (P < 
0.0001) for both testosterone and estrone sulfate. Plasma testosterone concentrations 
declined (p < 0.0038) by Day 1 of treatment, and testosterone concentrations remained 
suppressed relative to controls until the end of treatment (Fig. 3). After the last treatment, 
plasma testosterone concentrations in the acyline-treated stallions remained suppressed for 
9 days before returning to levels comparable to controls. The acyline-treated group showed 
a constant, steady suppression of peripheral testosterone, with mean concentration of 129 
pg/mL during treatment. There were significant time (P < 0.0001) and time-by-treatment 
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interactions (P < 0.0001) in plasma estrone sulfate concentrations, which were lower in 
treated than control stallions by Day 5 of treatment (p < 0.05). There was a steady 
suppression (p < 0.001) of estrone sulfate from day 6 to day 64 such that  the suppression 
of peripheral estrone sulfate lasted 14 days after the end of treatment (day 50) (Fig. 4). 
Plasma AMH concentrations even though subject to a time effect (P < 0.0001), were not 
affected by treatment (Fig. 5). 
Figure 1: Circulating FSH concentrations in acyline-treated and control stallions. Acyline-
treated stallions received 330g/kg of acyline every five days and controls received vehicle 
alone. Dashed lines represent treatment start and finish date. Data expressed as mean ± 
S.E.M. (*) or (*) indicate timepoints or intervals, respectively, where p<0.05. 
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Figure 2: Circulating LH concentrations in acyline-treated and control stallions. Acyline-
treated stallions received 330mg/kg of acyline every five days and controls received 
vehicle alone. Dashed lines represent treatment start and finish date. Data expressed as 
mean ± S.E.M.. (*) or (*) indicate timepoints or intervals, respectively, where p<0.05. 
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Figure 3: Plasma testosterone concentrations in acyline-treated and control stallions. 
Acyline-treated stallions received 330mg/kg of acyline every five days and controls 
received vehicle alone. Dashed lines represent treatment start and finish date Data 
expressed as mean ± S.E.M. The shaded area indicates the interval where p<0.05: Day 1 
through Day 59 
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Figure 4: Plasma estrone sulfate concentrations in acyline-treated and control stallions. 
Acyline-treated stallions received 330mg/kg of acyline every five days and controls 
received vehicle alone. Dashed lines represent treatment start and finish date. Data are 
expressed as mean ± S.E.M. The shaded area indicates the interval where p<0.05: Day 8 
through Day 64. 
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Figure 5: Plasma anti-Müllerian hormone (AMH) concentrations in acyline-treated and 
control stallions. Acyline-treated stallions received 330mg/kg of acyline every five days 
and controls received vehicle alone. Dashed lines represent treatment start and finish date. 
Data expressed as mean values ± S.E.M.  
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Response to GnRH stimulation was evaluated as area under the curve (AUC) for 
FSH, LH and testosterone before and during the treatment period. There were no 
differences in gonadotropin or testosterone responses between groups pre-treatment and 
during treatment in controls. However, acyline-treated stallions did not show a rise in FSH 
(p<0.0005), LH (p<0.0003) or testosterone (p<0.0007) in response to GnRH compared to 
the increase in those hormones during the pre-treatment period or relative to control values 
(Table 1).  
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Table 1: Response of FSH, LH and testosterone (AUC) to GnRH challenge pre-treatment 
and during treatment.  
AUC 
Pre-treatment During Treatment   
Control Acyline Control   Acyline   
FSH (ng/mL x 120min) 11.5 19.4 12.0 6.8* 
LH (ng/mL x 120min) 10.3 21.5 11.5 0.7* 
Testosterone  
(pg/mL x 120min) 
3364.6 5393.3 4143.2 373.7* 
* indicates statistical difference (p<0.05) in the same line 
B. Seminal parameters 
There was an effect of time (P < 0.0001) and a time-by-treatment interaction (P < 
0.0001) on total sperm number. Total sperm number increased in treated stallions at week 
1, but then declined and remained lower in treated than control stallions for the duration of 
the study (Fig. 6).  
There was also an effect of time (P < 0.0001) and time-by-treatment (P < 0.0001) 
on semen volume.  Gel free volume was higher in treated stallions in week 1 of treatment 
and decreased to lower than that for controls at weeks 2 and 8 but means were similar on 
all other weeks (Fig. 7). Concentration of sperm did not differ between treated and controls 
during any of the weeks of collections. 
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Figure 6: Total sperm numbers in acyline-treated and control stallions. Acyline-treated 
stallions received 330mg/kg of acyline every five days and controls received vehicle alone. 
Sperm count for DSO ejaculate shown as mean ± S.E.M. Dashed lines represent treatment 
start and finish date. (*) indicates time points where p<0.05; (**) indicates p<0.005.   
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Figure 7: Gel-free ejaculate volume in acyline-treated and control stallions. Acyline-
treated stallions received 330mg/kg of acyline every five days and controls received 
vehicle alone. Dashed lines represent treatment start and finish date. Volume on DSO 
ejaculates shown as mean ± S.E.M. (*) indicates time points where p<0.05.  
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Total sperm motility was lower in treated than control stallions by week 2 (p<0.05) 
and remained lower than controls through the end of treatment. A similar effect was 
observed in progressive motility, which was lower in treated than control stallions from 
week 2 (p<0.0028) to week 8 (p<0.003), with the exception of week 4 (p<0.06). Post-
treatment, both sperm motility parameters were similar in treated and control stallions (Fig. 
8). Sperm morphology evaluation did not yield any significant changes in number of 
morphologically abnormal spermatozoa. The number of round spermatogenic cells 
increased at weeks 2 and 8 in the treated group (Data not shown). 
Figure 8: Sperm motility in acyline-treated and control stallions. Acyline-treated stallions 
received 330mg/kg of acyline every five days and controls received vehicle alone. Total 
motility (a) and progressive motility (b), at DSO ejaculates, shown as mean ± S.E.M. 
Dashed lines represent treatment start and finish date. (*) indicates time points where 
p<0.05.  
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Total seminal plasma protein was lower from week 2 of treatment through the end 
of treatment and until the fourth week post-treatment (p<0.05); total seminal plasma protein 
was similar in both groups by week 6 of the recovery period and throughout the rest of the 
study (Fig. 9). Osmolality of seminal plasma samples was not changed due to treatment 
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(p<0.1649). (Fig. 10). There was a time effect (p<0.008) on osmolality with an increase 
during the treatment period and the beginning of the post-treatment period. Since there was 
no treatment by time effect, osmolality was plotted in the mixed model with number of 
mounts to ejaculation as a possible explanation for the unspecific fluctuation over time but 
no association was found between the two variables (data not shown).   
Figure 9: Seminal plasma total protein content in acyline-treated and control stallions. 
Acyline-treated stallions received 330mg/kg of acyline every five days and controls 
received vehicle alone. Weekly averages shown as mean values ± S.E.M. Dashed lines 
represent treatment start and finish date. (*) indicates time points where p<0.05.   
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Figure 10: Seminal plasma osmolality in acyline-treated and control stallions. Acyline-
treated stallions received 330mg/kg of acyline every five days and controls received 
vehicle alone. Weekly averages shown as mean values ± S.E.M. Dashed lines represent 
treatment start and finish date.  
 
Fig. 10 
C. Total testicular volume  
There was an effect of time (P<0.0001) and a time-by-treatment interaction (P < 
0.0001) on testis volume. Mean testis volume was lower in acyline-treated stallions by 
week 5 and remained lower throughout the treatment period (Fig 11). Testis volume 
increased in treated stallions during the post-treatment period and was not different from 
controls by week 12.  
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Figure 11: Total testicular volume in acyline-treated and control stallions. Acyline-treated 
stallions received 330mg/kg of acyline every five days and controls received vehicle alone. 
Weekly values shown as mean ± S.E.M. Dashed lines represent treatment start and finish 
date. (*) indicates time points where p<0.05. 
 
Fig. 11 
 
D. Reproductive behavior 
There was no effect of acyline treatment on time to erection or number of mounts. 
Towards the end of the treatment and beginning of recovery period treated stallions tended 
(p<0.08) to require longer to achieve an erection. A similar trend was seen for number of 
mounts required for ejaculation. At week 10, treated stallions required longer time (p<0.05) 
to achieve ejaculation (Fig. 12). A time effect was observed on all of the three variables 
(p<0.0001).  
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Figure 12: Time to ejaculation over time. Mean times, on weekly averages, are shown ± 
S.E.M. Data not transformed. 
 
12 
 
3.5. Discussion 
 
The primary mechanism of action of GnRH antagonists is a competitive blockade 
of the GnRH receptor in pituitary gonadotrophs precluding substantial occupation and 
stimulation by endogenous GnRH (Heber et al., 1982; Conn and Crowley, 1991; Huirne 
and Lambalk, 2001) which causes an immediate inhibition. This is in contrast to GnRH 
agonists, which require repeated administration to achieve this effect (Clayton and Catt, 
1980; Conn and Crowley, 1991) via down-regulation of GnRH receptors (Schally, 1999). 
Our findings clearly show a suppression of the hypothalamic-pituitary-gonadal axis in 
stallions treated with acyline. Down-regulation of the HPG axis was evident by a reduction 
in gonadotropins, testicular steroids, as well as diminished response to GnRH stimulation 
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during treatment with acyline. The suppression of the HPG axis was associated with 
changes in testis volume, DSO, total seminal plasma protein as well as sperm motility and, 
to some extent, behavioral modification. Discontinuation of treatment enabled the axis to 
resume functionality based on return of FSH, LH, estrone sulfate and testosterone to normal 
circulating concentrations, followed by resumption of the majority of the seminal and 
testicular parameters. 
Administration of other GnRH antagonists has been used in the stallion to examine 
downregulation of the HPG axis. A single dose of Antarelix to stallions resulted in no 
suppression of testosterone, a slight suppression of LH and a marked reduction in  FSH 
and  estradiol (Hinojosa et al., 2001), although when Antarelix or Cetrorelix were 
administered twice daily for 5 weeks (Fortier et al., 2002), testosterone was decreased until 
a week after the end of treatment. Findings on testosterone suppression  during treatment 
with acyline in stallions agrees with those in men (Herbst et al., 2002; Herbst et al., 2004) 
and dogs (Garcia Romero et al., 2009), and levels of testosterone were consistent with 
concentration of geldings – lower than 130-200pg/mL (Dowsett et al., 1996; Malmgren et 
al., 2001). The depth of suppression of the HPG axis during acyline treatment was 
demonstrated by a lack of response in FSH, LH or testosterone to GnRH stimulation in 
treated stallions compared to controls and to pre-treatment response of treated stallions. 
These results are similar to what has been reported in dogs (Garcia Romero et al., 2012b). 
Previous studies investigating downregulation of HPG in stallions have utilized different 
approaches, but acyline provides a more rapid and consistent downregulation when 
compared to altrenogest (Brady et al., 1997; Miller et al., 1997; Squires et al., 1997; 
Johnson et al., 1998; Heninger et al., 2001) and anti-GnRH vaccination (Dowsett et al., 
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1996; Malmgren et al., 2001; Clement et al., 2005; Turkstra et al., 2005; Burger et al., 
2006; Janett et al., 2009). 
Anti-Müllerian hormone is produced by Sertoli cells and differentially expressed 
in prepubertal, postpubertal and cryptorchid stallions (Ball et al., 2008). AMH peripheral 
concentration decreases with sexual maturity, though secretion into circulation remains 
high in cryptorchids (Claes et al., 2013). Given the suppression in Leydig cell activity and 
spermatogenesis of acyline-treated stallions, one can assume that changes in FSH and 
steroid hormones are also having an impact on Sertoli cell metabolism. Not much is known 
about the regulation of AMH in the male, though the lack of effect of HPG suppression on 
AMH concentrations may suggest that regulatory mechanisms for AMH secretion are apart 
from the HPG axis. 
Reduced sperm output was somewhat expected given the endocrinological changes 
and is in accordance with previous work using GnRH antagonists in the stallion where a 
drop of almost 50% in sperm output after a single injection was noted (Hinojosa et al., 
2001). In the study by Fortier et al. there was a near absence of sperm in the ejaculate at 
the end of treatment (Fortier et al., 2002). In dogs, acyline did not suppress spermatogenesis 
completely in all of the subjects after a single injection, but it was sufficient to cause 
azoospermia in four of seven treated dogs (Valiente et al., 2007). In the present study, even 
though reproductive hormones, particularly steroids, were strongly suppressed, sperm 
numbers were still about one third of those during pre-treatment. It is intriguing that sperm 
output of stallions increased in the first week of acyline treatment then dropped in the 
following week. Since extra-gonadal reserves had been depleted, this may indicate a 
hastening of the outflow of sperm cells from spermiation until reaching the cauda 
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epididymis. There was a 10-15% loss in total motility and 10-25% drop in progressive 
motility, with total motility reaching a nadir of about 35%. Conversely, Hinojosa et al. 
(Hinojosa et al., 2001) did not find effects of the antagonist on sperm motility following a 
single injection of GnRH antagonist. In humans, contraception has been cited as a potential 
use for acyline, though it seems that the partial persistence of motile sperm in the ejaculate 
of treated stallions precludes the use of this antagonist as a contraceptive in the male equine. 
The decreased testicular volume during treatment with acyline is in line with the sperm 
numbers present in the ejaculates and was also reported in acyline-treated dogs (Valiente 
et al., 2007).  
The appearance of round spermatogenic cells was also noticed in dogs receiving 
acyline (Valiente et al., 2007), and in stallions given Antarelix and Cetrorelix, in which 
testicular histology exhibited loss of round spermatogenic cells into the lumen 8 weeks 
after administration (Hinojosa et al., 2001). The increased number of round cells in acyline 
treated stallions at weeks two and eight, in particular, seems to agree with these previous 
publications. Further explanation for these findings may come from studies on GnRH 
antagonist in rats. As observed histologically, inhibition of meiosis in a high percentage of 
the seminiferous tubules  resulted in only 22% of seminiferous tubules containing 
elongated spermatids in a 30-day long treatment (Szende et al., 1990), while in a 60-day 
long treatment spermatocytes were the most advanced germ cell form detected, signifying 
a spermatogenic arrest (Bokser et al., 1991). 
Normal function of the accessory sex glands of stallions (Gebauer et al., 1976; 
Thompson Jr. et al., 1980) and the epididymis of various species (Amann, 2011), depends 
on testosterone and estrogen (Thompson Jr. et al., 1980; Parlevliet et al., 2006), and these 
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structures are responsible for producing the protein components of the seminal plasma 
(Weber and Woods, 1993; Koskinen et al., 2002; Amann, 2011). Thus, the transient 
decrease observed in total protein content of the seminal plasma of treated stallions seems 
logical.  
After castration in the study by Thompson and colleagues (Thompson Jr. et al., 
1980), the desire to mount was retained for longer than the ability of stallions to ejaculate. 
Despite the strong suppression of both testosterone and estrone sulfate seen in the present 
study with acyline, changes in libido were only evident in respect to the increased time to 
ejaculation at week 10, while there was no significant change in time for erection. That 
seems to agree with the idea that there are at least two aspects of sexual behavior displayed 
by stallions: desire to mount and thrust, and ability to ejaculate (Thompson Jr. et al., 1980; 
Wallach et al., 1983). 
Though the study was not designed to evaluate seasonality, there was a time effect 
in a number of parameters, which may be explained by the months when the experiment 
was conducted. The general increase in time to erection and time to ejaculation in the fall 
months agrees with previous reports (Pickett et al., 1976; Thompson et al., 1977; Clay et 
al., 1987). Variations due to season have been reported in testosterone (Berndtson et al., 
1974; Thompson et al., 1977; Clay et al., 1987; Claes et al., 2013), testicular size (Clay et 
al., 1987), sperm output (Pickett et al., 1976; Thompson et al., 1977; Clay et al., 1987) and 
also for AMH (Claes et al., 2013).  
After discontinuation of treatment the persistence of a depression in LH, FSH, 
testosterone and estrone sulfate is worth noting. The suppression of testosterone for at least 
nine days after last treatment showed that the effect of serial administrations of the GnRH 
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antagonist led to a suppression of the HPG axis for about double the time it did after a 
single injection. A more extended suppression in FSH and LH following a series of GnRH 
antagonist injections compared to single injection was also seen in humans (Behre et al., 
1997). It was demonstrated in rats that, in fact, the amount of GnRH receptors (Srkalovic 
et al., 1990; Bokser et al., 1991; Halmos et al., 1996; Murase et al., 2005) and GnRHr 
mRNA (Pinski et al., 1996; Murase et al., 2005) were decreased due to GnRH antagonist 
treatment. This contrasts with the previous idea that GnRH antagonists exerted their effects 
purely by competition for GnRH receptors. From a practical standpoint, doses of acyline 
could be progressively reduced during a treatment with repeated doses, or low doses given 
after a high, loading dose, as was suggested for GnRH antagonists in humans (Behre et al., 
1997), thus possibly reducing the cost of treating a stallion 
As observed in the present study, a rebound effect on FSH and LH after 
discontinuation of GnRH antagonist treatment was noticed in men (Behre et al., 1997). 
After a single injection of acyline in dogs, a rebound was noticed in FSH, but not LH 
(Garcia Romero et al., 2009); a testosterone peak was also noticed after recovery of the 
suppression in dogs (Garcia Romero et al., 2009; Garcia Romero et al., 2012b), but no 
significant rebound occurred in testosterone concentration in acyline-treated stallions. 
While sperm output was study the only parameter in the present that did not return 
to normal levels during the recovery period, recrudescence of the testicular parenchyma 
might serve as an indication that sperm production would also return to baseline numbers. 
As postulated by Berndtson and co-authors (Berndtson et al., 1974), an interval of 
approximately 60 days is needed between the testicular insult affecting spermatogenesis in 
the stallion and appearance of a maximal response measured as sperm output. Even though 
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the recovery period (72 days) was long enough for  production of new sperm and 
epididymal transit (Amann, 2011), it may not have been sufficiently long if one takes into 
consideration the delay in return of gonadotropins and steroids to normality. Nevertheless, 
a follow up in the following breeding season, as part of another experiment 7 months after 
the end of the recovery period, showed that all of the sperm numbers at DSO, obtained 
after every-other-day collections for 14 days, had returned to normal, though it is 
impossible to precisely determine when the recovery in sperm production occurred. Hints 
for the recrudescence of spermatogenesis may be gathered from reported return of sperm 
output to normality at 75 days after the end of treatment with Antarelix and Cetrorelix in 
stallions (Fortier et al., 2002), and by evidence that sperm germ cell differentiation, stalled 
due to GnRH antagonist in rats, had fully recovered 90 days after cessation of treatment 
(Bokser et al., 1991).  
Change in behavior due to acyline, though slighter, recovered more readily than 
with anti-GnRH vaccination (Burger et al., 2006; Janett et al., 2009). A survey published 
by Line and others (Line et al., 1985) indicated that after surgical castration at least 30% 
of stallions continued to display some kind of aggressive behavior after castration. That 
agrees with the notion that aggressive behavior in stallions is not solely caused by 
reproductive behavior (McDonnell, 1986, 2000). If gonadal removal itself cannot resolve 
all of the behavioral issues in stallions, it seems that a pharmacological approach with 
reversible effects on libido, might be preferable to castration in certain situations. Other 
experiments are necessary to investigate if the effects of acyline on sexual behavior are 
sufficient for the desired application in resolving aggressive behavior in a training or 
competition environment. 
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Surgical castration of EAV shedding stallions resulted in cessation of virus 
shedding in semen as early as 4 days, though other stallions required over 25 days (Little 
et al., 1991). In our study, the fifth day after acyline injections, when the next dose was to 
be administered, was part of the assay schedule. Taking aside physiological fluctuations in 
circulating testosterone during the day, those time-points are presumably the lowest 
suppression by the GnRH antagonist and, consequently, the highest concentrations of 
testosterone during acyline treatment. Therefore, we believe that the gelding-like 
testosterone concentrations shown as result of acyline treatment truthfully represent the 
levels of this steroid throughout the entire treatment period. While, unfortunately, we had 
no opportunity to use EAV stallions for this trial, it can be speculated, based on immuno-
castration (Burger et al., 2006) and GnRH antagonists (Fortier et al., 2002) that the 
reduction on testosterone levels brought by acyline should be adequate to promote virus 
clearance in the semen of EAV persistent carriers. 
In conclusion, acyline treatment rapidly down regulates the HPG axis in stallions. 
Reduction in gonadotropins, testosterone and estrone sulfate was followed by a decline in 
sperm output and motility, seminal plasma proteins and testicular volume, while there was 
an increase in round spermatogenic cells present in the ejaculate of treated stallions. Lastly, 
sexual behavior was affected by an increase in time for ejaculation in acyline–treated 
stallions. Suppression of the HPG axis by acyline was also demonstrated by failure of 
stallions under treatment to respond to exogenous GnRH stimulus. Upon cessation of 
treatment, most of the affected parameters returned to control values within 72 d; though 
sperm output may require longer to recover. Further experiments are necessary to 
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determine the applicability of acyline as treatment for EAV carrier stallions and for 
behavior modulation. 
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Chapter Four: Summary and conclusions 
The administration of 330µg/kg acyline every five days for 50 days suppressed the 
hypothalamic-pituitary-gonadal (HPG) axis in stallions. Down-regulation of the HPG axis 
was reflected by a reduction in FSH, LH, testosterone and estrone sulfate. The lack of 
responsiveness to GnRH stimulation during treatment with acyline illustrates the strength 
of the inhibition of the HPG axis due to acyline treatment. This GnRH antagonist treatment 
also caused a decrease in testis volume, total sperm output, sperm motility and total seminal 
plasma protein content. That indicates the impairment of the activity of the testes as well 
as epididymides and accessory sex glands. Finally, to some extent, certain sexual 
behavioral traits seemed to be affected by acyline administration. A transient increase in 
round spermatogenic cells in semen was observed, which supports the presumed arrest on 
spermatogenic meiosis. Discontinuation of treatment enabled the HPG axis to resume its 
activity based on a return of FSH, LH, estrone sulfate and testosterone to normal circulating 
concentrations, followed by resumption of the testicular and most of seminal parameters 
investigated within a 72-day recovery period. 
From the day following the first acyline injection, testosterone was reduced to 
gelding levels throughout the treatment period in acyline-treated stallions. Data derived 
from investigations regarding castration, immuno-castration and GnRH antagonists in 
EAV carrier stallions serve as reference on the suppression of androgens to induce 
clearance from EAV persistently infective state in stallions. Even though the stallions used 
in this experiment were not infected with EAV to testify this hypothesis, the reduction on 
testosterone brought by acyline might be adequate to promote clearance of virus presence 
in the semen of EAV persistent carriers. Despite the marked suppression in hormonal 
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profiles, spermatogenesis was not completely interrupted and sperm motility was only 
partially lost. Changes seen in libido, as measured by latency for ejaculation, seem to agree 
with the idea that there are at least two aspects of sexual behavior displayed by stallions: 
desire to mount and thrust, and ability to ejaculate. Since physical castration appears not to 
resolve all of the cases in which exacerbated sexual behavior is an issue, a chemical 
approach for castration cannot be expected to have better results and a treatment with 
GnRH antagonists may be appropriate as a substitute. Upon cessation of treatment, 
testosterone required longer to return to baseline than after a single injection, which may 
be explained by the down-regulation of GnRH receptors on the gonadotrophs. From a 
practical perspective, that may indicate a potential for decreasing the dosage of GnRH 
antagonist as treatment progresses while same suppressive effect is achieved. 
 In conclusion, acyline provided a more rapid and consistent downregulation of the 
HPG than various previous approaches used in stallions. The transient suppression was 
characterized by decline in gonadotropins and steroid hormones, which resulted in decrease 
of testicular volume and seminal parameters – including sperm output and motility, 
increase in round germ cells and decrease in seminal plasma proteins. Sexual behavior was 
also affected by acyline. After discontinuation of treatment, all of the parameters returned 
to their pretreatment levels. Further studies with acyline are necessary to determine the 
length of treatment that would be sufficient to reliably clear EAV from shedding stallions 
without returning to shedding state after treatment discontinuation. As a treatment for 
behavior modification future studies would include stallions and young colts at training or 
competition treated with acyline to verify the extent of its effects and usefulness in those 
settings.
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